Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...